Eindhoven, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) has completed its first field study for its Minicare handheld cardiac Troponin-I (cTn-I) blood test, demonstrating the platform’s potential to produce lab-equivalent results with finger prick samples within minutes.
Share the Post
About the Author
Philips Respironics, a global leader in the sleep and respiratory markets, is passionate about providing solutions that lead to healthier patients, healthier practices, and healthier businesses. For us, innovation is driven by gaining insight into the needs of the people who use our products in the areas of sleep apnea management, oxygen therapy, noninvasive ventilation and respiratory drug delivery.